UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activation of AKT PKB in breast cancer predicts a worse outcome among endocrine treated patients

British journal of cancer, 2002-02, Vol.86 (4), p.540-545

2002

Volltextzugriff (PDF)

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

Journal of clinical oncology, 2022-12, Vol.40 (35), p.4071-4082

2022

Volltextzugriff (PDF)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

International journal of cancer, 2022-06, Vol.150 (12), p.2072-2082

2022

Volltextzugriff (PDF)

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype

Journal of cancer research and clinical oncology, 2019-07, Vol.145 (7), p.1845-1856

2019

Volltextzugriff (PDF)

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

Breast cancer research : BCR, 2013-01, Vol.15 (5), p.R96-R96, Article R96

2013

Volltextzugriff (PDF)

EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer

Oncotarget, 2016-04, Vol.7 (16), p.21362-21380

2016

Volltextzugriff (PDF)

Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer

Breast cancer research and treatment, 2015-08, Vol.153 (1), p.31-40

2015

Volltextzugriff (PDF)

Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients

Cancers, 2022-10, Vol.14 (19), p.4844

2022

Volltextzugriff (PDF)

Met and its ligand HGF are associated with clinical outcome in breast cancer

Oncotarget, 2016-06, Vol.7 (24), p.37145-37159

2016

Volltextzugriff (PDF)

S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts

Endocrine-related cancer, 2015-06, Vol.22 (3), p.331-343

2015

Volltextzugriff (PDF)

Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial

JAMA network open, 2021-06, Vol.4 (6), p.e2114904-e2114904

2021

Volltextzugriff (PDF)

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer

European journal of cancer (1990), 2013-04, Vol.49 (6), p.1196-1204

2013

Volltextzugriff (PDF)

PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer

Clinical cancer research, 2007-06, Vol.13 (12), p.3577-3584

2007

Volltextzugriff (PDF)

68P 20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials

Annals of oncology, 2022-05, Vol.33, p.S153-S154

2022

Volltextzugriff (PDF)

Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells

International journal of oncology, 2005-01, Vol.26 (1), p.25

2005

Volltextzugriff (PDF)

6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer

Annals of oncology, 2021-05, Vol.32, p.S23

2021

Volltextzugriff (PDF)

LBA1 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

Annals of oncology, 2021-05, Vol.32, p.S21

2021

Volltextzugriff (PDF)

Akt kinases in breast cancer and the results of adjuvant therapy

Breast cancer research : BCR, 2003-01, Vol.5 (2), p.R37-R44, Article R37

2003

Volltextzugriff (PDF)

125P Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab

Annals of oncology, 2016-12, Vol.27, p.ix37-ix37

2016

Volltextzugriff (PDF)

25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer

ANNALS OF ONCOLOGY, 2021, Vol.32, p.S23

2021

Volltextzugriff (PDF)

20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

ANNALS OF ONCOLOGY, 2021, Vol.32, p.S21

2021

Volltextzugriff (PDF)

IP6K2 predicts favorable clinical outcome of primary breast cancer

Molecular and clinical oncology, 2021-05, Vol.14 (5), p.94-94, Article 94

2021

Volltextzugriff (PDF)

20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials

ANNALS OF ONCOLOGY, 2022, Vol.33, p.S153

2022

Volltextzugriff (PDF)

Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer

International journal of oncology, 2006-05, Vol.28 (5), p.1031-1042

2006

Volltextzugriff (PDF)

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

British journal of cancer, 2002-02, Vol.86 (4), p.540-545

2002

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(30)
Tagungsberichte
(5)

Sprache

Erscheinungsjahr

n.n

Thema

Medicin Och Hälsovetenskap
(21)
Life Sciences & Biomedicine
(18)
Oncology
(18)
Science & Technology
(18)
Humans
(16)
Female
(15)
Breast Cancer
(13)
Prognosis
(11)
Breast Neoplasms - Drug Therapy
(9)
Tumors
(9)
Akt
(8)
Breast Neoplasms - Genetics
(8)
Tamoxifen - Therapeutic Use
(8)
Breast Neoplasms - Metabolism
(7)
Gene Expression
(7)
Immunohistochemistry
(7)
Medicine
(7)
Middle Aged
(7)
Breast Neoplasms - Pathology
(6)
Antineoplastic Agents, Hormonal - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Activation of AKT PKB in breast cancer predicts a worse outcome among endocrine treated patients

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer

Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer

Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients

Met and its ligand HGF are associated with clinical outcome in breast cancer

S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts

Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer

PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer

68P 20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials

Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells

6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer

LBA1 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

Akt kinases in breast cancer and the results of adjuvant therapy

125P Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab

25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer

20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

IP6K2 predicts favorable clinical outcome of primary breast cancer

20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials

Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

Suchergebnisse filtern